<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JPS</journal-id><journal-title-group><journal-title>Journal of Physiology Studies</journal-title></journal-title-group><issn pub-type="epub">2330-1589</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/JPS.2018.64005</article-id><article-id pub-id-type="publisher-id">JPS-27089</article-id><article-categories><subj-group subj-group-type="heading"><subject>JPS20180400000_30536854.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>生命科学</subject><subject> 医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  人胰淀素的研究进展
  An Updated Review of Human Amylin
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>伟洁</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>彦超</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>凌</surname><given-names>伟</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>海潞</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>桂林医学院，广西糖尿病系统医学重点实验室，广西免疫学重点学科，广西 桂林</addr-line></aff><aff id="aff2"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>30</day><month>09</month><year>2018</year></pub-date><volume>06</volume><issue>04</issue><fpage>27</fpage><lpage>33</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   人胰淀素(hIAPP)是由胰岛细胞合成分泌、37个氨基酸组成的多肽类激素，与胰岛素、胰高血糖素等协同调节糖稳态。hIAPP可表现为生理药理状态下的单体(monomer)以及病理状态下的寡聚体(oligomer，α-螺旋结构)与纤维体(fibril，β片层折叠)。hIAPP单体的生理药理功能如下：1) 影响胰岛素与胰高血糖素的分泌；2) 延缓胃排空，降低餐后血糖；3) 升高肾素与血管紧张素II，调节肾生长；4) 升高醛固酮，降低血钙；5) 调节骨密度；6) 舒张血管，调节血流动力学；7) 调节免疫效应。hIAPP单体可诱导调节T细胞分化，从而调节炎症反应和免疫因子的分泌。部分一过性hIAPP寡聚体可引发胰岛β细胞凋亡，造成β细胞功能失常。由hIAPP纤维体折叠形成的淀粉样沉积，可保护胰岛避免自身免疫攻击。hIAPP不足或者hIAPP纤维体缺乏，是自身免疫性糖尿病的特征。hIAPP在肥胖以及糖尿病、自身免疫、骨质疏松等疾病的防治过程中，具有潜在应用前景。 Human amylin/islet amyloid polypeptide (hIAPP) is a 37-amino acid polypeptide synthesized and secreted from islet β-cells. hIAPP orchestrates with insulin and glucagon to maintain glucose homeostasis. Conformation of the physiological-pharmacological hIAPP monomers can transform into an α-helical oligomer and eventually β-pleated sheet fibrils. The physiological-pharmacological effects of hIAPP monomers are as follows: 1) playing with insulin and glucagon to regulate blood glucose levels, 2) delaying gastric empty, 3) modulating renal growth by increased levels of renin, angiotensin II, and aldosterone, 4) lowering blood calcium level by calcitonin-like action, 5) regu-lating bone density and minimizing the risk of osteoporosis, 6) dilating blood vessels for homodynamic changes, and 7) modulating autoimmune response predominantly by the induction of regu-latory T cells and regulation of cytokines and inflammatory reactions. The autoimmune-modulating action of hIAPP is a rather novel finding. The transient hIAPP oliomers might be toxic and have implicated in the islet β-cell apoptosis and dysfunction. Islet amyloid deposits dominantly com-promising of hIAPP fibrils may be protective against self-destruction in autoimmune diabetes. Therefore, the neuroendocine hIAPP indeed has multiple potentials in the prevention and treatment of chronic diseases such as obesity, diabetes, autoimmune disorder, and osteoporosis. 
    
  
 
</p></abstract><kwd-group><kwd>人胰淀素，胰岛淀粉样沉积，糖尿病，糖稳态，自身免疫, hIAPP</kwd><kwd> Islet Amyloid</kwd><kwd> Diabetes</kwd><kwd> Glucose Homeostasis</kwd><kwd> Autoimmune Disease</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>人胰淀素的研究进展<sup> </sup></title><p>吴伟洁，王彦超，凌伟，赵海潞<sup>*</sup></p><p>桂林医学院，广西糖尿病系统医学重点实验室，广西免疫学重点学科，广西 桂林</p><disp-formula id="hanspub.27089-formula7"><graphic xlink:href="//html.hanspub.org/file/2-2870050x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2018年9月19日；录用日期：2018年10月4日；发布日期：2018年10月10日</p><disp-formula id="hanspub.27089-formula8"><graphic xlink:href="//html.hanspub.org/file/2-2870050x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>人胰淀素(hIAPP)是由胰岛b细胞合成分泌、37个氨基酸组成的多肽类激素，与胰岛素、胰高血糖素等协同调节糖稳态。hIAPP可表现为生理药理状态下的单体(monomer)以及病理状态下的寡聚体(oligomer，a-螺旋结构)与纤维体(fibril，b片层折叠)。hIAPP单体的生理药理功能如下：1) 影响胰岛素与胰高血糖素的分泌；2) 延缓胃排空，降低餐后血糖；3) 升高肾素与血管紧张素II，调节肾生长；4) 升高醛固酮，降低血钙；5) 调节骨密度；6) 舒张血管，调节血流动力学；7) 调节免疫效应。hIAPP单体可诱导调节T细胞分化，从而调节炎症反应和免疫因子的分泌。部分一过性hIAPP寡聚体可引发胰岛b细胞凋亡，造成b细胞功能失常。由hIAPP纤维体折叠形成的淀粉样沉积，可保护胰岛避免自身免疫攻击。hIAPP不足或者hIAPP纤维体缺乏，是自身免疫性糖尿病的特征。hIAPP在肥胖以及糖尿病、自身免疫、骨质疏松等疾病的防治过程中，具有潜在应用前景。</p><p>关键词 :人胰淀素，胰岛淀粉样沉积，糖尿病，糖稳态，自身免疫</p><disp-formula id="hanspub.27089-formula9"><graphic xlink:href="//html.hanspub.org/file/2-2870050x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/2-2870050x8_hanspub.png" /> <img src="//html.hanspub.org/file/2-2870050x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 前言</title><p>糖尿病(diabetes mellititus, DM)是内分泌与代谢失常导致的常见慢性病。前期，我们通过前瞻性研究观察华人2型DM 2906例(其中胰岛素治疗971例)，连续随访7年。横断面资料研究中美国2型DM 25,964例，英国2型DM 84,622例。发现注射胰岛素虽可快速降糖，然而显著增加2型DM临床终点事件风险。死亡、癌症、慢性并发症、低血糖与危症是主要临床终点。随着DM人群还在迅速扩大，胰岛素使用者并发癌症、冠心病、脑中风、慢性肾病、低血糖的风险不断攀升 [<xref ref-type="bibr" rid="hanspub.27089-ref1">1</xref>]。目前胰岛素是被广泛用于DM的临床治疗的常规药物。胰岛素由胰腺胰岛β细胞分泌，是机体内唯一降低血糖的经典激素，同时促进糖原、脂肪、蛋白质合成。胰岛β细胞除了分泌胰岛素外，还同时分泌的另一激素：人胰淀素(hIAPP)又称胰淀素(Amylin)，是与DM密切相关，且有望成为治疗糖尿病药物另一被逐渐认识的新兴激素，本文关注hIAPP的研究进展及其应用探索。</p></sec><sec id="s4"><title>2. 胰淀素的历史发现</title><p>hIAPP的由来最早可追溯到1901年，Opie观察到糖尿病(DM)患者胰腺胰岛组织中出现有透明样变、沉积的物质 [<xref ref-type="bibr" rid="hanspub.27089-ref2">2</xref>]。1987年由瑞典病理学家Westermark P.和牛津大学的新西兰学者Cooper G.分别从人胰岛素瘤和2型DM胰腺组织中发现 [<xref ref-type="bibr" rid="hanspub.27089-ref3">3</xref>][<xref ref-type="bibr" rid="hanspub.27089-ref4">4</xref>]，该“透明样变性”的物质主要成分是由胰岛β细胞分泌的、由37氨基酸组成多肽，并分别把它命名为胰岛淀粉样多肽(islet amyloid polypeptide, IAPP)和胰淀素(Amylin) [<xref ref-type="bibr" rid="hanspub.27089-ref5">5</xref>]。随后瑞典病理学家Westermark P.用免疫组化的方法证实 [<xref ref-type="bibr" rid="hanspub.27089-ref6">6</xref>]，90%的2型DM患者在胰岛内均有Amylin沉积 [<xref ref-type="bibr" rid="hanspub.27089-ref7">7</xref>]。</p></sec><sec id="s5"><title>3. 胰淀素的分子构象</title><p>如图1所示，人胰淀素(Human IAPP, hIAPP)单体(monomer)由37个氨基酸组成，分子量为3850 Delton，基因位于第12对染色体短臂上 [<xref ref-type="bibr" rid="hanspub.27089-ref8">8</xref>]，包括3个外显子和2个内含子，第22~27，23~27及20~29位氨基酸序列在一定条件下可随机聚集，形成一过性的、呈现α-螺旋结构样寡聚体(oligomer)。寡聚体进一步折叠、均质排列、形成β-折叠片层结构(β-pleated sheet)，最终构成一个僵硬网状、没有分枝、直径8~10 nm的纤维体，即淀粉样沉积物，在偏光显微镜下呈双折光，刚果红染色在荧光显微镜下呈现苹果绿色 [<xref ref-type="bibr" rid="hanspub.27089-ref9">9</xref>]，中间第20~29位氨基酸的组成具有种属差异性。分子中第二和第七位半胱氨酸残基之间形成二硫键，对hIAPP的分子生物学功能的完整性有重要作用 [<xref ref-type="bibr" rid="hanspub.27089-ref10">10</xref>]；分子两端有短链修饰，羟基末端酰胺化(如图2所示)。hIAPP基因经转录、翻译成89肽pre-pro-IAPP，翻译后N氮末端22个氨基酸被清除，67肽proIAPP进入胰岛β-细胞内质网腔，前蛋白转化酶作用于二价碱基氨基酸，将67肽前胰淀素转变为hIAPP—37肽(IAPP)；hIAPP与降钙素基因相关肽高度同源，与人的降钙素基因相关肽((calcitonin gene related peptide，CGRP)和降钙素(calcitonin, CT)的氨基酸同源序列分别达50%和20% [<xref ref-type="bibr" rid="hanspub.27089-ref11">11</xref>]，在生理功能上也有相类似功效如扩张血管、抑制胃酸分泌和抑制胰岛素分泌等。所以hIAPP是不仅仅属于淀粉样纤维蛋白家族，具备该家族共同的所有组织化学和分子结构特征，还被划分为降钙素基因相关肽家族。其氨基酸分子可表现为单体、寡聚物、原纤维体三种不同构象 [<xref ref-type="bibr" rid="hanspub.27089-ref12">12</xref>]。hIAPP单体具有调节葡萄糖与脂质稳态平衡的生理功能；当hIAPP氨基酸基因序列错误折叠形成寡聚物(一过性中间体)时，它具有细胞毒性作用；寡聚物进一步累积形成b片状结构，即不溶性无毒的hIAPP原纤维。</p><p>图1. 胰淀素单体–寡聚体(α-螺旋结构)–纤维体(β片层折叠)构象变化</p><p>图2. 胰岛β-细胞中67肽前体裂解为37肽胰淀素的过程 [<xref ref-type="bibr" rid="hanspub.27089-ref13">13</xref>]</p></sec><sec id="s6"><title>4. 胰淀素的生理效应</title><p>2型DM患者胰腺胰岛组织内出现的透明样变、沉积物质，在人胰岛素瘤组织中可出现。正常人胰岛组织中含有与胰岛素阳性相当数量的hIAPP阳性细胞，血液中hIAPP含量也与血胰岛素水平密切相关 [<xref ref-type="bibr" rid="hanspub.27089-ref14">14</xref>]。1型DM病人胰岛组织内和血液里几乎检测不到hIAPP [<xref ref-type="bibr" rid="hanspub.27089-ref15">15</xref>]；胰岛素抵抗和高胰岛素血症的患者，hIAPP的含量也高 [<xref ref-type="bibr" rid="hanspub.27089-ref16">16</xref>]；需要胰岛素控制血糖的2型DM病人胰腺组织内和血液里的hIAPP水平低下 [<xref ref-type="bibr" rid="hanspub.27089-ref17">17</xref>]。hIAPP是构成胰岛淀粉样变的主要组分。电镜和免疫组化染色显示，hIAPP与胰岛素共同储存在人胰岛β细胞的分泌颗粒中，当受到像葡萄糖等物质正常刺激时，以不同量比(1:100)，同时分泌。当hIAPP处于高浓度时，会抑制胰岛素的分泌；也抑制胰高血糖素分泌的高峰，从而降低餐后血糖，是胰岛素的一种伴侣激素，与胰高血糖素一起调节人体内糖稳态，因此也被定义为一种神经内分泌激素。无论在鼠类还是人体中，hIAPP可以延缓胃排空，减慢小肠吸收葡萄糖速度，延长吸收入血的时间，降低餐后血糖。hIAPP结合大脑神经元细胞膜上hIAPP受体，受体介导信号转导影响下丘脑的摄食中枢，产生饱食效应，从而hIAPP也被称为饱胀因子，延长进食后的饱胀感，最终减少食物的摄入量 [<xref ref-type="bibr" rid="hanspub.27089-ref18">18</xref>]。hIAPP可以抑制肌糖原的合成，刺激氧化反应和低密度脂蛋白的吸收，也会导致脂质样效应。机制虽尚不明确，但hIAPP具有抑制骨吸收，也有刺激成骨细胞增殖的作用，在骨质疏松的发生发展中起重要作用 [<xref ref-type="bibr" rid="hanspub.27089-ref19">19</xref>]- [<xref ref-type="bibr" rid="hanspub.27089-ref24">24</xref>]。hIAPP不仅仅升高肾素与肾素血管紧张素II，调节肾生长等肾脏系统的影响，还有升高醛固酮、引起低钙血症、舒张血管调节血流动力学的效应。</p></sec><sec id="s7"><title>5. 胰淀素的效应辨析</title><p>自hIAPP从1901年以“透明样变性”的物质被发现，当时被预测与DM的发病相关，瑞典病理学家Westermark P.用免疫组化的方法证实，90%的2型DM患者胰岛内均有IAPP沉积，所以认为沉积的IAPP可通过损伤β细胞而参与2型DM的发病过程。胰岛淀粉样变是人类2型DM的病理特征 [<xref ref-type="bibr" rid="hanspub.27089-ref25">25</xref>]。现主流观点认为hIAPP有调节糖代谢和胰岛素、胰高血糖素等相关激素分泌的作用。也有诸多研究显示，hIAPP沉积在胰岛表面形成的淀粉蛋白纤维，损伤胰岛细胞，导致胰岛素抵抗，所以通常被认为是致病因素 [<xref ref-type="bibr" rid="hanspub.27089-ref26">26</xref>]，不利于胰岛细胞存活，不利于糖尿病病人的康复，对于此问题争议一直不断 [<xref ref-type="bibr" rid="hanspub.27089-ref27">27</xref>][<xref ref-type="bibr" rid="hanspub.27089-ref28">28</xref>]。</p><p>因此自hIAPP发现以来，hIAPP与糖尿病的关系就一直为人关注因此，从1999年至2010年，我们曾经收集了多家医院病理科436例2型DM的尸检组织样本以及相应临床资料 [<xref ref-type="bibr" rid="hanspub.27089-ref29">29</xref>]，详细观察了胰腺组织改变，系统研究了胰岛淀粉样变的临床病理学特征，结果显示hIAPP有可能具有重要内分泌调节作用 [<xref ref-type="bibr" rid="hanspub.27089-ref30">30</xref>]。在体内外研究hIAPP的生物学功能和药理疗效过程中 [<xref ref-type="bibr" rid="hanspub.27089-ref12">12</xref>]，发现其与胰岛素共同调节机体糖稳态的同时，hIAPP还可以通过诱导调节T淋巴(Treg)细胞生成，调节炎症反应和免疫因子分泌，有效改善免疫病理反应，在自身免疫病、组织器官移植以及炎症病理等方面具有重要的作用。</p><p>胰岛淀粉样沉积只是DM病人胰岛细胞呈现的过程结局，至今为止，没有证据直接证明hIAPP淀粉样沉积导致糖尿病。相反，在所有胰岛表面形成淀粉样沉积的DM病人中，胰岛素的分泌相对不足，属于慢性胰岛细胞损伤进程，而不是绝对缺乏、急性损伤死亡导致的结果。所以，hIAPP在DM病人胰岛表面形成的淀粉样沉积很可能是延缓胰岛细胞损伤死亡的过程，从而起到保护胰岛细胞的作用。由此可见，hIAPP不仅仅在餐后血糖控制、进食行为和体重控制中起着重要作用 [<xref ref-type="bibr" rid="hanspub.27089-ref18">18</xref>]，与胰岛素、胰高血糖素共同调节机体的糖稳态。犹如DM不仅仅涉及血糖分泌问题，更涉及代谢与免疫调节等整体问题 [<xref ref-type="bibr" rid="hanspub.27089-ref31">31</xref>]。hIAPP不仅仅是人体中重要的内分泌激素，也具备免疫调节作用。</p></sec><sec id="s8"><title>6. 胰淀素的应用探索</title><p>hIAPP的类似物普兰林肽(pramlintide)作为1型与2型DM辅助用药的治疗效果呈现良好的正性作用 [<xref ref-type="bibr" rid="hanspub.27089-ref32">32</xref>]，已经投放市场，应用于临床。如何将hIAPP的功能效应，应用到DM的治疗中成了至关重要的命题。在此，不得不回顾治疗糖尿病的经典激素，胰岛素。1921年Banting和Best首次从狗的胰腺中成功获得了胰岛素，第二年即应用于临床。30年代时，开始生产结晶猪胰岛素，70年代时，创立生产猪胰岛素的简便方法。从1922年到1982年的60年间，应用于临床的主要是猪胰岛素，而国外主要是牛胰岛素。原先胰岛素的来源是从牛胰脏提取，产量非常有限 [<xref ref-type="bibr" rid="hanspub.27089-ref33">33</xref>]。随着基因工程的发展，后来用大肠杆菌化工合成的方式产生人重组胰岛素，使得胰岛素从动物胰岛素转化为人胰岛素。随着技术的不断发展，通过基因定位突变和表达，得到聚合度低的单体速效胰岛素 [<xref ref-type="bibr" rid="hanspub.27089-ref34">34</xref>]，并且在临床中得到广泛的应用。</p><p>然而，无论是长效胰岛素还是短效胰岛素，其给药途径均是直接注射入血的方式。当药物直接释放入血的时候，机体会产生抗体，从而引起抗原抗体反应，引起自身免疫反应。如今国际制药企业常规利用动物组织、酵母与大肠杆菌等微生物载体，生产重组人体胰岛素过程中不可避免产生内毒素的弊端。同时，化学合成或者提纯的化学药物，存在一般药物固有的难题—耐药性以及各种不良反应。DM患者需要承受注射用药、口服用药所引起的疼痛、心理的负担以及各种副反应，胰岛素的系统性风险日益突出。</p><p>hIAPP的应用探索，重点在如何避免药物生产与应用的弊端，寻找到经得起时间与疾病考验的用药方式上。免疫组化显示：hIAPP不仅存在于胰岛β细胞的分泌颗粒中，同时在人体胃肠道内分泌细胞、甲状腺、肺、心脏等内脏神经元、大脑神经元等处均有分布 [<xref ref-type="bibr" rid="hanspub.27089-ref26">26</xref>]。hIAPP可以通过常规口服的服药方式，药物经过肠道-上皮-黏膜吸收，激活胃肠道上皮细胞的hIAPP受体从而发挥其作用，属于局部吸收。另外，华夏民族的饮食养生一般讲究以“五谷为养，五果为助，五畜为益，五菜为充”为原则，历来有药食同源习俗。如何通过植物(Plant)作为天然“工厂”(Plant)，生产具有调控糖代谢作用的重要蛋白–hIAPP，或通过hIAPP介入日常饮食中，用于糖尿病的防治，以及改善相关的免疫病理有不可替代的优势，值得更进一步探索与研究。</p></sec><sec id="s9"><title>7. 胰淀素的研究展望</title><p>hIAPP在2型DM患者的胰岛淀粉样沉积物和人胰岛素瘤等病理变化中发现，从单体随机变化为寡聚体，最终可消除淀粉样沉积中的纤维体，从生理现象变化为细胞毒作用的病理现象，最终抑或起到延缓疾病进程的药理效应。hIAPP不同的构型标志着不同的功用，标志着其不同的生理–病理–药理阶段，也反映着机体不同的反应。hIAPP的研究重点不在于hIAPP本身扮演的是一个疾病或健康、有利或有弊的角色，而在于引起其角色变换的主体以及主体对其角色的需求与改变。hIAPP是影响着人体多种重要激素之一，更是影响肥胖、DM、糖稳态、免疫病理、骨质疏松等慢性病为数不多的激素之一。如何在研究中把单一的hIAPP，用以改善多靶点、整体性的糖稳态失衡以及其他相关疾病的发生发展，需要未来更多的考证、探索与研究。</p></sec><sec id="s10"><title>基金项目</title><p>国家自然科学基金面上项目(81471054)；广西研究生教育创新计划项目“病理-生理-药理学一体化课程教学改革与实践”(JGY2015128)；广西高校中青年教师基础能力提升项目(2018KY0416)。</p></sec><sec id="s11"><title>文章引用</title><p>吴伟洁,王彦超,凌 伟,赵海潞. 人胰淀素的研究进展An Updated Review of Human Amylin[J]. 生理学研究, 2018, 06(04): 27-33. https://doi.org/10.12677/JPS.2018.64005</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.27089-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">牟学晶, 任欣欣, 赵海潞. 胰岛素治疗的系统风险[J]. 临床合理用药杂志, 2014(20): 12-14.</mixed-citation></ref><ref id="hanspub.27089-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">El, O. (1901) The Relation oe Diabetes Mellitus to Lesions of the Pancreas. Hyaline Degeneration of the Islands oe Langerhans. Journal of Experimental Medicine, 5, 527-540. &lt;br&gt;https://doi.org/10.1084/jem.5.5.527</mixed-citation></ref><ref id="hanspub.27089-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Höppener, J.W.M., Ahrén, B. and Lips, C.J.M. (2000) Islet Amyloid and Type 2 Diabetes Mellitus. New England Journal of Medicine, 343, 411-419. &lt;br&gt;https://doi.org/10.1056/NEJM200008103430607</mixed-citation></ref><ref id="hanspub.27089-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Westermark, P., Wernstedt, C., Wilander, E., et al. (1987) Amyloid Fi-brils in Human Insulinoma and Islets of Langerhans of the Diabetic Cat Are Derived from a Neuropeptide-Like Protein Also Present in Normal Islet Cells. Proceedings of National Academy of Sciences of USA, 84, 3881-3885. &lt;br&gt;https://doi.org/10.1073/pnas.84.11.3881</mixed-citation></ref><ref id="hanspub.27089-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Leighton, B. and Cooper, G.J. (1988) Pancreatic Amylin and Calcitonin Gene-Related Peptide Cause Resistance to Insulin in Skeletal Muscle in Vitro. Nature, 335, 632-635. &lt;br&gt;https://doi.org/10.1038/335632a0</mixed-citation></ref><ref id="hanspub.27089-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Hull, R.L., Westermark, G.T., Westermark, P., et al. (2004) Islet Amyloid: A Critical Entity in the Pathogenesis of Type 2 Diabetes. Journal of Clinical Endocrinology &amp; Metabolism, 89, 3629. &lt;br&gt;https://doi.org/10.1210/jc.2004-0405</mixed-citation></ref><ref id="hanspub.27089-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Johnson, K.H., O’Brien, T.D., Betsholtz, C., et al. (1989) Islet Amyloid, Is-let-Amyloid Polypeptide, and Diabetes Mellitus. New England Journal of Medicine, 321, 513-518. &lt;br&gt;https://doi.org/10.1056/NEJM198908243210806</mixed-citation></ref><ref id="hanspub.27089-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Johnson, K.H., O’Brien, T.D., Betsholtz, C., et al. (1992) Islet Amyloid Polypeptide: Mechanisms of Amyloidogenesis in the Pancreatic Islets and Potential Roles in Diabetes Mellitus. Laboratory Investi-gation: A Journal of Technical Methods and Pathology, 66, 522-535.</mixed-citation></ref><ref id="hanspub.27089-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Booth, D.R., Sunde, M., Bellotti, V., et al. (1997) Insta-bility, Unfolding and Aggregation of Human Lysozyme Variants Underlying Amyloid Fibrillogenesis. Nature, 385, 787-793. &lt;br&gt;https://doi.org/10.1038/385787a0</mixed-citation></ref><ref id="hanspub.27089-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Westermark, P., Andersson, A. and Westermark, G.T. (2011) Islet Amyloid Polypeptide, Islet Amyloid, and Diabetes Mellitus. Physiological Reviews, 91, 795. &lt;br&gt;https://doi.org/10.1152/physrev.00042.2009</mixed-citation></ref><ref id="hanspub.27089-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Wimalawansa, S.J. (1996) Calcitonin Gene-Related Peptide and Its Receptors: Molecular Genetics, Physiology, Pathophysiology, and Therapeutic Potentials. Endocrine Reviews, 17, 533-585. &lt;br&gt;https://doi.org/10.1210/edrv-17-5-533</mixed-citation></ref><ref id="hanspub.27089-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, X.X., Pan, Y.H., Huang, Y.M., et al. (2016) Neuroendocrine Hormone Amylin in Diabetes. World Journal of Diabetes, 7, 189-197. &lt;br&gt;https://doi.org/10.4239/wjd.v7.i9.189</mixed-citation></ref><ref id="hanspub.27089-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Marzban, L., Tri-go-Gonzalez, G., Zhu, X., et al. (2004) Role of Beta-Cell Prohormone Convertase (PC)1/3 in Processing of Pro-Islet Amyloid Poly-peptide. Diabetes, 53, 141-148. &lt;br&gt;https://doi.org/10.2337/diabetes.53.1.141</mixed-citation></ref><ref id="hanspub.27089-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, H.L., Lai, F.M., Tong, P.C., et al. (2003) Prevalence and Clinicopathological Characteristics of Islet Amyloid in Chinese Patients with Type 2 Diabetes. Diabetes, 52, 2759-2766. &lt;br&gt;https://doi.org/10.2337/diabetes.52.11.2759</mixed-citation></ref><ref id="hanspub.27089-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Qiao, Y.C., Shen, J., Hong, X.Z., et al. (2016) Changes of Regu-latory T Cells, Transforming Growth Factor-Beta and Interleukin-10 in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Clinical Immunology, 170, 61-69. &lt;br&gt;https://doi.org/10.1016/j.clim.2016.08.004</mixed-citation></ref><ref id="hanspub.27089-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Westermark, G.T., Gebre-Medhin, S. and Westermark, D.F.S. (2000) Islet Amyloid Development in a Mouse Strain Lacking Endogenous Islet Amyloid Polypeptide (IAPP) But Expressing Human IAPP. Molecular Medicine, 6, 998-1007. &lt;br&gt;https://doi.org/10.1007/BF03402051</mixed-citation></ref><ref id="hanspub.27089-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Johnson, K.H., O’Brien, T.D., Hayden, D.W., et al. (1988) Immunolocalization of Islet Amyloid Polypeptide (IAPP) in Pancreatic Beta Cells by Means of Peroxidase-Antiperoxidase (PAP) and Protein A-Gold Tech-niques. American Journal of Pathology, 130, 1-8.</mixed-citation></ref><ref id="hanspub.27089-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Schmitz, O., Brock, B. and Rungby, J. (2004) Amylin Agonists: A Novel Approach in the Treatment of Diabetes. Diabetes, 53, S233.</mixed-citation></ref><ref id="hanspub.27089-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Cornish, J., Callon, K.E., Cooper, G.J., et al. (1995) Amylin Sti-mulates Osteoblast Proliferation and Increases Mineralized Bone Volume in Adult Mice. Biochemical and Biophysical Research Communications, 207, 133-139.  
&lt;br&gt;https://doi.org/10.1006/bbrc.1995.1163</mixed-citation></ref><ref id="hanspub.27089-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Wimalawansa, S.J. (1997) Amylin, Calcitonin Gene-Related Peptide, Calcitonin, and Adrenomedullin: A Peptide Superfamily. Critical Reviews in Neurobiology, 11, 167-239. &lt;br&gt;https://doi.org/10.1615/CritRevNeurobiol.v11.i2-3.40</mixed-citation></ref><ref id="hanspub.27089-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Cornish, J., Callon, K.E., Gasser, J.A., et al. (2000) Systemic Ad-ministration of a Novel Octapeptide, Amylin-(1-8), Increases Bone Volume in Male Mice. American Journal of Physiology Endo-crinology and Metabolism, 279, E730-E735. &lt;br&gt;https://doi.org/10.1152/ajpendo.2000.279.4.E730</mixed-citation></ref><ref id="hanspub.27089-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Horcajada-Molteni, M.N., Davicco, M.J., Lebecque, P., et al. (2000) Amylin Inhibits Ovariectomy-Induced Bone Loss in Rats. The Journal of Endocrinology, 165, 663-668. &lt;br&gt;https://doi.org/10.1677/joe.0.1650663</mixed-citation></ref><ref id="hanspub.27089-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Bronsky, J. and Prusa, R. (2004) Amylin Fasting Plasma Levels Are Decreased in Patients with Osteoporosis. Osteoporosis International: A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 15, 243-247.  
&lt;br&gt;https://doi.org/10.1007/s00198-003-1538-5</mixed-citation></ref><ref id="hanspub.27089-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Bronsky, J., Prusa, R. and Nevoral, J. (2006) The Role of Amylin and Related Peptides in Osteoporosis. International Journal of Clinical Chemistry, 373, 9-16.</mixed-citation></ref><ref id="hanspub.27089-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, H.L., Tong, P.C., Lai, F.M., et al. (2004) Association of Glomerulopathy with the 5’-End Polymorphism of the Aldose Reductase Gene and Renal Insufficiency in Type 2 Diabetic Patients. Diabetes, 53, 2984.  
&lt;br&gt;https://doi.org/10.2337/diabetes.53.11.2984</mixed-citation></ref><ref id="hanspub.27089-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Höppener, J.W., Ahrén, B. and Lips, C.J. (2000) Islet Amyloid and Type 2 Diabetes Mellitus. The New England Journal of Medicine, 343, 411-419. &lt;br&gt;https://doi.org/10.1056/NEJM200008103430607</mixed-citation></ref><ref id="hanspub.27089-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Cooper, G.J.S., Aitken, J.F. and Zhang, S. (2010) Is Type 2 Diabetes an Amyloidosis and Does It Really Matter (to Patients)? Diabetologia, 53, 1011-1016. &lt;br&gt;https://doi.org/10.1007/s00125-010-1715-y</mixed-citation></ref><ref id="hanspub.27089-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Hay, D.L., Chen, S., Lutz, T.A., et al. (2015) Amylin: Pharmacology, Physi-ology, and Clinical Potential. Pharmacological Reviews, 67, 564-600. &lt;br&gt;https://doi.org/10.1124/pr.115.010629</mixed-citation></ref><ref id="hanspub.27089-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, H.L., Sui, Y., Guan, J., et al. (2008) Higher Islet Amyloid Load in Men than in Women with Type 2 Diabetes Mellitus. Pancreas, 37, e68-e73. &lt;br&gt;https://doi.org/10.1097/MPA.0b013e3181788e18</mixed-citation></ref><ref id="hanspub.27089-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, H., Guan, J., Lee, H.M., et al. (2010) Up-Regulated Pan-creatic Tissue microRNA-375 Associates with Human Type 2 Diabetes through Beta-Cell Deficit and Islet Amyloid Deposition. Pancreas, 39, 843-846.  
&lt;br&gt;https://doi.org/10.1097/MPA.0b013e3181d12613</mixed-citation></ref><ref id="hanspub.27089-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Zheng, T., Qin, L., Chen, B., et al. (2016) Association of Plasma DPP4 Activity with Mild Cognitive Impairment in Elderly Patients with Type 2 Diabetes: Results from the GDMD Study in China. Di-abetes Care, 39, 1594-1601.  
&lt;br&gt;https://doi.org/10.2337/dc16-0316</mixed-citation></ref><ref id="hanspub.27089-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Qiao, Y.C., Ling, W., Pan, Y.H., et al. (2017) Efficacy and Safety of Pramlintide Injec-tion Adjunct to Insulin Therapy in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Oncotarget, 8, 66504-66515.  
&lt;br&gt;https://doi.org/10.18632/oncotarget.16008</mixed-citation></ref><ref id="hanspub.27089-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Wr, F. (1982) The Discovery of Insulin. McClelland and Stewart, Toron-to.</mixed-citation></ref><ref id="hanspub.27089-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Kurtzhals, P., Schäffer, L., Sørensen, A., et al. (2000) Correlations of Receptor Binding and Metabolic and Mitogenic Po-tencies of Insulin Analogs Designed for Clinical Use. Diabetes, 49, 999-1005.  
&lt;br&gt;https://doi.org/10.2337/diabetes.49.6.999</mixed-citation></ref></ref-list></back></article>